<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02824224</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY00015881</org_study_id>
    <nct_id>NCT02824224</nct_id>
  </id_info>
  <brief_title>Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)</brief_title>
  <official_title>Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the ability of tamoxifen to improve frequent or prolonged bleeding in
      new users of the 52mg levonorgestrel-releasing intrauterine device (IUD). Half of
      participants will receive a course of tamoxifen three weeks after insertion of the IUD, while
      the other half of participants will receive a course of placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New users of the LNG IUD will be eligible. Subjects will be randomized to receive tamoxifen
      10 mg twice daily for 7 days or placebo. Study drug will be started 3 weeks after placement
      of the IUD. Subjects will maintain a record of daily bleeding and spotting using an
      electronic text messaging diary.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 6, 2016</start_date>
  <completion_date type="Actual">January 8, 2018</completion_date>
  <primary_completion_date type="Actual">January 8, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Bleeding and Spotting Days</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
    <description>Mean number of bleeding and spotting days in the tamoxifen group compared to the mean number of bleeding and spotting days in the placebo group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bleeding Pattern Satisfaction</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
    <description>0-100 mm Visual Analog Scale (VAS) measurement of satisfaction with bleeding pattern. 0 mm = not at all satisfied, 100 mm = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IUD Satisfaction</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
    <description>0-100 mm Visual Analog Scale (VAS) measurement of satisfaction with IUD (intrauterine device). 0 mm = not at all satisfied, 100 mm = very satisfied.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>30 days after initiation of study drug</time_frame>
    <description>Descriptive reporting of adverse events for each arm</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Total Number of Bleeding/Spotting Episodes</measure>
    <time_frame>60 days after initiation of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of Prolonged Bleeding Episodes (&gt;8 Days)</measure>
    <time_frame>60 days after initiation of study drug</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Longest Bleed-free Interval</measure>
    <time_frame>60 days after initiation of study drug</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Menorrhagia</condition>
  <condition>Metrorrhagia</condition>
  <condition>Medicated Intrauterine Devices</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (for Tamoxifen)</intervention_name>
    <description>Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  initiating use of 52mg levonorgestrel-releasing IUD for contraceptive purposes

          -  access to reliable cell phone

          -  willing to receive and respond to daily text or email message to assess bleeding

        Exclusion Criteria:

          -  using IUD for indication other than contraception

          -  postpartum within 6 months, pregnant, or breastfeeding

          -  removal and replacement of IUD

          -  undiagnosed abnormal uterine bleeding prior to placement of IUD

          -  bleeding dyscrasia

          -  anti-coagulation use

          -  active cervicitis

          -  allergy to tamoxifen

          -  history of venous thromboembolism

          -  personal history of breast or uterine malignancy

          -  use of medication contraindicated with use of tamoxifen (coumadin, letrozole,
             bromocriptine, rifampicin, aminoglutethimide, phenobarbital)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Megan A Cohen, MD, MPH</last_name>
    <role>Study Director</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OHSU Center For Women's Health</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>July 2, 2016</study_first_submitted>
  <study_first_submitted_qc>July 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2016</study_first_posted>
  <results_first_submitted>April 8, 2019</results_first_submitted>
  <results_first_submitted_qc>May 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 21, 2019</results_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Jeffrey Jensen</investigator_full_name>
    <investigator_title>Leon Speroff Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>levonorgestrel</keyword>
  <keyword>breakthrough bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menorrhagia</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT02824224/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Excluded (n=5) from participation after signing informed consent form. Discontinued IUD (n=1) Declined to participate (n=2) Non-compliant with diaries (n=2)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tamoxifen</title>
          <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued, IUS expulsion</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not show up for allocation visit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Tamoxifen</title>
          <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="34"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.6" spread="7.6"/>
                    <measurement group_id="B2" value="28.8" spread="6.1"/>
                    <measurement group_id="B3" value="29.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White, non-Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Bleeding and Spotting Days</title>
        <description>Mean number of bleeding and spotting days in the tamoxifen group compared to the mean number of bleeding and spotting days in the placebo group</description>
        <time_frame>30 days after initiation of study drug</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bleeding and Spotting Days</title>
          <description>Mean number of bleeding and spotting days in the tamoxifen group compared to the mean number of bleeding and spotting days in the placebo group</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" spread="9.0"/>
                    <measurement group_id="O2" value="12.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bleeding Pattern Satisfaction</title>
        <description>0-100 mm Visual Analog Scale (VAS) measurement of satisfaction with bleeding pattern. 0 mm = not at all satisfied, 100 mm = very satisfied.</description>
        <time_frame>30 days after initiation of study drug</time_frame>
        <population>Only 30 women completed the side effect, satisfaction and acceptability survey (n=15 placebo and n=15 tamoxifen).</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Pattern Satisfaction</title>
          <description>0-100 mm Visual Analog Scale (VAS) measurement of satisfaction with bleeding pattern. 0 mm = not at all satisfied, 100 mm = very satisfied.</description>
          <population>Only 30 women completed the side effect, satisfaction and acceptability survey (n=15 placebo and n=15 tamoxifen).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.7" spread="28.6"/>
                    <measurement group_id="O2" value="58.6" spread="31.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>IUD Satisfaction</title>
        <description>0-100 mm Visual Analog Scale (VAS) measurement of satisfaction with IUD (intrauterine device). 0 mm = not at all satisfied, 100 mm = very satisfied.</description>
        <time_frame>30 days after initiation of study drug</time_frame>
        <population>Only 30 women completed the side effect, satisfaction and acceptability survey (n=15 placebo and n=15 tamoxifen).</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>IUD Satisfaction</title>
          <description>0-100 mm Visual Analog Scale (VAS) measurement of satisfaction with IUD (intrauterine device). 0 mm = not at all satisfied, 100 mm = very satisfied.</description>
          <population>Only 30 women completed the side effect, satisfaction and acceptability survey (n=15 placebo and n=15 tamoxifen).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.7" spread="22.0"/>
                    <measurement group_id="O2" value="75.3" spread="21.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Descriptive reporting of adverse events for each arm</description>
        <time_frame>30 days after initiation of study drug</time_frame>
        <population>Adverse event information is reported in &quot;Adverse Event&quot; section of record summary.</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Descriptive reporting of adverse events for each arm</description>
          <population>Adverse event information is reported in &quot;Adverse Event&quot; section of record summary.</population>
          <units>Events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Total Number of Bleeding/Spotting Episodes</title>
        <time_frame>60 days after initiation of study drug</time_frame>
        <population>Study ended up only collecting 30-day follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Bleeding/Spotting Episodes</title>
          <population>Study ended up only collecting 30-day follow up data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Prolonged Bleeding Episodes (&gt;8 Days)</title>
        <time_frame>60 days after initiation of study drug</time_frame>
        <population>Study ended up only collecting 30-day follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Prolonged Bleeding Episodes (&gt;8 Days)</title>
          <population>Study ended up only collecting 30-day follow up data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Longest Bleed-free Interval</title>
        <time_frame>60 days after initiation of study drug</time_frame>
        <population>Study ended up only collecting 30-day follow up data</population>
        <group_list>
          <group group_id="O1">
            <title>Tamoxifen</title>
            <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Longest Bleed-free Interval</title>
          <population>Study ended up only collecting 30-day follow up data</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after initiating study medication.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tamoxifen</title>
          <description>Tamoxifen 10mg tablet by mouth twice daily for 7 days
Tamoxifen: 10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo tablet (for tamoxifen tablet) by mouth twice daily for 7 days
Placebo (for Tamoxifen): Sugar pill manufactured to mimic the tamoxifen 10mg tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Mood changes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ob/Gyn Regulatory Specialist</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>5034940757</phone>
      <email>mccrimmo@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

